The document provides statistics on the sources of treatment for diabetes. Insulin accounts for 35% of treatment, followed by sulfonylureas (SU) at 31% and metformin at 14%. DPP-4 inhibitors and TZDs each account for 14% and 6% respectively. The document then briefly discusses the history of diabetes treatment from ancient Persia to modern therapies. It advocates recommending the therapy best suited for each diabetic patient. The rest of the document discusses marketing strategies like societal marketing of diabetes education and continuing medical education programs to promote societal marketing based products. It also lists the top diabetes drug brands by prescriptions.